miRecule and GBI Biomanufacturing Announce Strategic Partnership to Advance Development of Antibody RNA Conjugate (ARC) Therapies | PR Newswire [Video]

PLANTATION, Fla.  and GAITHERSBURG, Md., Jan. 28, 2025 /PRNewswire/ — miRecule, a biotechnology company pioneering RNA therapies, and GBI Biomanufacturing, a leading contract development and manufacturing organization (CDMO), today announced a strategic partnership to advance the development and clinical supply of miRecule’s innovative Antibody-RNA Conjugate (ARC) based products.

Under the agreement, GBI will leverage its expertise and state-of-the-art facilities to support miRecule in the development and clinical production of its ARC therapies. These therapies combine the precision of antibody targeting with the efficacy of oligonucleotide-based therapeutics, representing a significant advancement in the treatment of challenging and rare diseases with unmet medical need.

“Our collaboration with GBI marks a significant milestone in advancing our ARC technology to address the genetic causes of serious diseases. Their expertise in conjugationtechnologies and antibody manufacturing makes them an ideal partner to efficiently propel our ARC programs into clinical development, with the potential to deliver meaningful benefits …